KR940005274A - 쇼그렌(Sjoegren)증후군 치료제 - Google Patents

쇼그렌(Sjoegren)증후군 치료제 Download PDF

Info

Publication number
KR940005274A
KR940005274A KR1019930012594A KR930012594A KR940005274A KR 940005274 A KR940005274 A KR 940005274A KR 1019930012594 A KR1019930012594 A KR 1019930012594A KR 930012594 A KR930012594 A KR 930012594A KR 940005274 A KR940005274 A KR 940005274A
Authority
KR
South Korea
Prior art keywords
addition salt
acid addition
aryl
alkyl
methylspiro
Prior art date
Application number
KR1019930012594A
Other languages
English (en)
Other versions
KR100331046B1 (ko
Inventor
노부아끼 아베
야스요시 다께시다
Original Assignee
쑈노 가쯔야
유끼지루시유꼬 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940005274(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쑈노 가쯔야, 유끼지루시유꼬 가부시끼가이샤 filed Critical 쑈노 가쯔야
Publication of KR940005274A publication Critical patent/KR940005274A/ko
Application granted granted Critical
Publication of KR100331046B1 publication Critical patent/KR100331046B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

[구성]스피로옥사티오란퀴누클리딘유도체 또는 그 산부가염을 유효성분으로 하는 쇼그렌증후군치료제.
[효과]2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘염산부가염을 쓰면 쇼그렌증후군을 치료할수가 있다. 구체적으로는 구내건조증, 눈안의 건조증 또는 건조성각막염등의 병태를 개선 또는 치료할수가 있다.
[선택도]없음

Description

쇼그렌(Sjoegren)증후군 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예(2)의 방법에 의한 퀴누클리딘염산부가염(식Ⅱ)투여후 방치시간과 침분비량의 관계를 나타낸다.

Claims (3)

  1. 다음의 일반식(Ⅰ)로써 표시되는 스피로옥사티오란퀴누클리딘유도체 또는 그 산부가염을 유효성분으로 하는 쇼그렌증후군치료제.
    [식중, Z는) CR1, R2또는 두개의 수소원자이고, R1및 R2는 동일하거나 달라도 좋고, 각각 알킬, 시크로벤틸, 시크로헥실, 아릴 또는 디아릴메티롤 또는 1개 이상의 아릴기로 치환된 알킬로서 R1과 R2의 어느쪽이나 한쪽이 수소이어도 좋다).
  2. 제1항에 있어서, 스피로옥사티오란 퀴노클리딘유도체 산부가염이 다음의 화학식(Ⅱ)로 표시되는 2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘 염산부가염인 쇼그렌증후군치료제.
  3. 제2항에 있어서, 2-메틸스피로(1,3-옥사티오란-5,3')퀴누클리딘염산부가염인 쇼그렌증후군치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930012594A 1992-07-10 1993-07-06 쇼그렌증후군치료제 KR100331046B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4207485A JP2683783B2 (ja) 1992-07-10 1992-07-10 シェーグレン症候群治療剤
JP92-207485 1992-07-10

Publications (2)

Publication Number Publication Date
KR940005274A true KR940005274A (ko) 1994-03-21
KR100331046B1 KR100331046B1 (ko) 2002-08-19

Family

ID=16540522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930012594A KR100331046B1 (ko) 1992-07-10 1993-07-06 쇼그렌증후군치료제

Country Status (15)

Country Link
US (1) US5340821A (ko)
EP (1) EP0578511B1 (ko)
JP (1) JP2683783B2 (ko)
KR (1) KR100331046B1 (ko)
AT (1) ATE184483T1 (ko)
AU (1) AU666734B2 (ko)
CA (1) CA2099970C (ko)
DE (1) DE69326395T2 (ko)
DK (1) DK0578511T3 (ko)
ES (1) ES2138613T3 (ko)
IL (1) IL106218A (ko)
NO (1) NO303765B1 (ko)
NZ (1) NZ248099A (ko)
TW (1) TW230750B (ko)
ZA (1) ZA934883B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852608B2 (ja) * 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
JP4447685B2 (ja) * 1999-01-14 2010-04-07 第一三共株式会社 皮膚乾燥症治療剤
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
EP1712230A1 (en) * 2004-10-05 2006-10-18 Astellas Pharma Inc. Pharmaceutical composition for xerophthalmia and xerostomia treatment
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8143400B2 (en) * 2008-01-10 2012-03-27 Apotex Pharmachem Inc. Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2498771E (pt) 2009-11-12 2014-01-30 Acacia Pharma Ltd Uso do betanecol para o tratamento de xerostomia
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
CN102846607A (zh) * 2012-04-09 2013-01-02 珠海亿邦制药股份有限公司 一种以盐酸西维美林为活性成分的固体制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001396A (en) * 1971-08-04 1977-01-04 Chinoin Pharmaceutical And Chemical Works Ltd. Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) * 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
US4855290A (en) * 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
US4684727A (en) * 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) * 1986-01-10 1987-11-25 Israel State Derivatives of quinuclidine
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
CA1303503C (en) * 1987-11-10 1992-06-16 Marc Plamondon Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4997654A (en) * 1989-08-14 1991-03-05 Warner-Lambert Company Method for increasing salivation for xerostomia patients
DE69220258T2 (de) * 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung

Also Published As

Publication number Publication date
EP0578511B1 (en) 1999-09-15
KR100331046B1 (ko) 2002-08-19
EP0578511A1 (en) 1994-01-12
AU666734B2 (en) 1996-02-22
JPH0624981A (ja) 1994-02-01
NO303765B1 (no) 1998-08-31
AU4181993A (en) 1994-01-13
NO932520L (no) 1994-01-11
TW230750B (ko) 1994-09-21
ES2138613T3 (es) 2000-01-16
CA2099970A1 (en) 1994-01-11
IL106218A (en) 1997-02-18
JP2683783B2 (ja) 1997-12-03
CA2099970C (en) 2003-12-30
US5340821A (en) 1994-08-23
DE69326395D1 (de) 1999-10-21
DK0578511T3 (da) 2000-04-03
ATE184483T1 (de) 1999-10-15
NO932520D0 (no) 1993-07-09
DE69326395T2 (de) 2000-04-20
IL106218A0 (en) 1993-11-15
ZA934883B (en) 1994-02-03
NZ248099A (en) 1999-07-29

Similar Documents

Publication Publication Date Title
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR940007022A (ko) 피패리딘 유도체, 이것의 제법 및 치료에 있어서 이것의 이용
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR930005972A (ko) N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR910004191A (ko) 신질환치료제
KR900001715A (ko) Bu-3608 유도체
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR950010896A (ko) 근시의 예방 및 치료용 조성물
KR900018128A (ko) 카르복스아미드 유도체
DE69001004T2 (de) Zusammensetzung gegen leberkrankheiten.
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도
KR910015301A (ko) 수면 무호흡증의 치료방법
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
KR890003372A (ko) 피리미도[2,1-b] 벤조티아졸 유도체로된 동맥경화 치료의약
KR890012961A (ko) N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘
KR920002594A (ko) 5-이소티아졸아민 유도체
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법
KR930019640A (ko) 테트라히드로피리미딘 유도체
KR910011258A (ko) 녹내장의 치료방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
E902 Notification of reason for refusal
B701 Decision to grant
N231 Notification of change of applicant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 12

EXPY Expiration of term